MX346147B - Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico. - Google Patents
Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico.Info
- Publication number
- MX346147B MX346147B MX2014010509A MX2014010509A MX346147B MX 346147 B MX346147 B MX 346147B MX 2014010509 A MX2014010509 A MX 2014010509A MX 2014010509 A MX2014010509 A MX 2014010509A MX 346147 B MX346147 B MX 346147B
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- isoquinolin
- aryl
- substituted
- tnks1
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title abstract 2
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 abstract 6
- 101000663006 Homo sapiens Poly [ADP-ribose] polymerase tankyrase-1 Proteins 0.000 abstract 3
- 101000662592 Homo sapiens Poly [ADP-ribose] polymerase tankyrase-2 Proteins 0.000 abstract 3
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 abstract 3
- 102100037664 Poly [ADP-ribose] polymerase tankyrase-1 Human genes 0.000 abstract 3
- 102100037477 Poly [ADP-ribose] polymerase tankyrase-2 Human genes 0.000 abstract 3
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- 230000011664 signaling Effects 0.000 abstract 3
- 230000001668 ameliorated effect Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
- C07D217/24—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Virology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Cardiology (AREA)
- Child & Adolescent Psychology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261607680P | 2012-03-07 | 2012-03-07 | |
| PCT/GB2013/050561 WO2013132253A1 (en) | 2012-03-07 | 2013-03-07 | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2014010509A MX2014010509A (es) | 2014-10-14 |
| MX346147B true MX346147B (es) | 2017-03-09 |
Family
ID=47891779
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2014010509A MX346147B (es) | 2012-03-07 | 2013-03-07 | Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9193689B2 (OSRAM) |
| EP (1) | EP2822656B1 (OSRAM) |
| JP (1) | JP6082409B2 (OSRAM) |
| KR (1) | KR102104144B1 (OSRAM) |
| CN (1) | CN104302358B (OSRAM) |
| AU (1) | AU2013229229B2 (OSRAM) |
| CA (1) | CA2865511A1 (OSRAM) |
| DK (1) | DK2822656T3 (OSRAM) |
| ES (1) | ES2611504T3 (OSRAM) |
| IN (1) | IN2014MN01875A (OSRAM) |
| MX (1) | MX346147B (OSRAM) |
| RU (1) | RU2696572C2 (OSRAM) |
| WO (1) | WO2013132253A1 (OSRAM) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2822656B1 (en) | 2012-03-07 | 2016-10-19 | Institute of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| SI2882714T1 (sl) * | 2012-08-08 | 2020-03-31 | Merck Patent Gmbh | (aza-)izokinolinonski derivati |
| CA2922469A1 (en) * | 2013-09-11 | 2015-03-19 | Institute Of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| DK3356345T3 (da) * | 2015-09-30 | 2024-02-12 | Max Planck Gesellschaft | Heteroaryl-derivater som sepiapterin-reduktase-inhibitorer |
| JP6930972B2 (ja) | 2015-12-02 | 2021-09-01 | シンジェンタ パーティシペーションズ アーゲー | 殺微生物性オキサジアゾール誘導体 |
| UY37623A (es) | 2017-03-03 | 2018-09-28 | Syngenta Participations Ag | Derivados de oxadiazol tiofeno fungicidas |
| WO2018219773A1 (en) | 2017-06-02 | 2018-12-06 | Syngenta Participations Ag | Fungicidal compositions |
| BR112019024984A2 (pt) | 2017-06-02 | 2020-06-23 | Syngenta Participations Ag | Derivados de oxadiazol microbicidas |
| JP7171634B2 (ja) | 2017-06-28 | 2022-11-15 | シンジェンタ パーティシペーションズ アーゲー | 殺菌性組成物 |
| WO2019011928A1 (en) | 2017-07-11 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
| WO2019011926A1 (en) | 2017-07-11 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
| WO2019011923A1 (en) | 2017-07-11 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
| WO2019011929A1 (en) | 2017-07-11 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
| WO2019012011A1 (en) | 2017-07-12 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
| WO2019012003A1 (en) | 2017-07-13 | 2019-01-17 | Syngenta Participations Ag | MICROBIOCIDE OXADIAZOLE DERIVATIVES |
| US12402885B2 (en) | 2017-09-23 | 2025-09-02 | Universität Zürich | Medical occlusion device |
| EP3459469A1 (en) | 2017-09-23 | 2019-03-27 | Universität Zürich | Medical occluder device |
| AR114136A1 (es) | 2017-10-10 | 2020-07-29 | Hoffmann La Roche | Compuestos heterocíclicos |
| US20210267204A1 (en) | 2018-07-16 | 2021-09-02 | Syngenta Crop Protection Ag | Microbiocidal oxadiazole derivatives |
| HUE064377T2 (hu) | 2019-04-12 | 2024-03-28 | Riboscience Llc | Biciklusos heteroaril-származékok mint ektonukleotid pirofoszfatáz foszfodiészteráz 1 inhibitorok |
| AR118673A1 (es) * | 2019-04-18 | 2021-10-20 | Syngenta Crop Protection Ag | Procedimiento para la preparación de derivados de oxadiazol microbiocidas |
| JP7531236B2 (ja) | 2019-09-26 | 2024-08-09 | ウニベルシタット チューリッヒ | 左心耳閉鎖デバイス |
| CN114929673B (zh) * | 2019-10-30 | 2025-06-06 | 多临生物株式会社 | 异喹啉酮衍生物、其制备方法和其用途 |
| US11972017B2 (en) | 2020-10-21 | 2024-04-30 | Verint Americas Inc. | System and method of automated determination of use of sensitive information and corrective action for improper use |
| EP4308664A1 (de) | 2021-03-18 | 2024-01-24 | Merck Patent GmbH | Heteroaromatische verbindungen für organische elektrolumineszenzvorrichtungen |
| EP4334278A4 (en) * | 2021-05-04 | 2025-08-06 | Univ Texas | INDANONE AND TETRALONE-KETO OR HYDROXYL OXIMES AS CANCER THERAPEUTIC AGENTS |
| CN115572262B (zh) * | 2022-10-27 | 2024-08-27 | 厦门沃克沃德医药科技有限公司 | 一种异喹啉衍生物及其制备方法 |
| WO2024238871A1 (en) * | 2023-05-18 | 2024-11-21 | Rectify Pharmaceuticals, Inc. | Aryl sulfonamide compounds and their use in treating medical conditions |
| GB2634228A (en) * | 2023-10-02 | 2025-04-09 | Duke Street Bio Ltd | PARP1 inhibitor compounds |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2851458A (en) | 1955-06-08 | 1958-09-09 | Burroughs Wellcome Co | Diquaternary compounds and the manufacture thereof |
| US3464563A (en) | 1967-02-06 | 1969-09-02 | American Air Filter Co | Liquid filter apparatus |
| US4678500A (en) | 1984-06-29 | 1987-07-07 | E. I. Du Pont De Nemours And Company | Herbicidal 2,6-disubstituted benzylsulfonamides and benzenesulfamates |
| US5177075A (en) | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
| US4942163A (en) | 1989-03-07 | 1990-07-17 | E. I. Du Pont De Nemours And Company | 1(2H)-isoquinolinones and 1-isoquinolineamines as cancer chemotherapeutic agents |
| WO1999018077A1 (fr) | 1997-10-02 | 1999-04-15 | Eisai Co., Ltd. | Derives de pyridine condenses |
| US6878714B2 (en) | 2001-01-12 | 2005-04-12 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| EP1396488A1 (en) | 2001-05-23 | 2004-03-10 | Mitsubishi Pharma Corporation | Fused heterocyclic compound and medicinal use thereof |
| KR100908176B1 (ko) | 2001-09-21 | 2009-07-16 | 브리스톨-마이어스스퀴브컴파니 | 인자 Ｘａ 억제제로서의 락탐-함유 화합물 및 그의 유도체 |
| MY140680A (en) | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| NZ537793A (en) * | 2002-07-24 | 2007-05-31 | Kyorin Seiyaku Kk | 4-(substituted aryl)-5-hydroxyisoquinolinone derivative |
| ATE552252T1 (de) * | 2002-10-01 | 2012-04-15 | Mitsubishi Tanabe Pharma Corp | Isochinolinverbindungen und deren medizinische verwendung |
| AP2021A (en) | 2002-10-23 | 2009-08-03 | Glenmark Pharmaceuticals Ltd | Novel tricyclic compounds useful for the treatmentof inflammatory and allergic disorders: Process f or their preparation and pharmaceutical compositions containing them |
| ATE496893T1 (de) | 2002-12-20 | 2011-02-15 | X Ceptor Therapeutics Inc | Isochinolinonderivate und deren verwendung als medikamente |
| DE602004019518D1 (de) | 2003-04-16 | 2009-04-02 | Bristol Myers Squibb Co | Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus |
| TW200536830A (en) | 2004-02-06 | 2005-11-16 | Chugai Pharmaceutical Co Ltd | 1-(2H)-isoquinolone derivative |
| WO2005075432A1 (ja) | 2004-02-06 | 2005-08-18 | Chugai Seiyaku Kabushiki Kaisha | １−（２ｈ）−イソキノロン誘導体およびその抗ガン剤としての使用 |
| WO2005113540A1 (ja) | 2004-05-20 | 2005-12-01 | Mitsubishi Pharma Corporation | イソキノリン化合物及びその医薬用途 |
| US8093273B2 (en) | 2004-10-20 | 2012-01-10 | Resverlogix Corp. | Flavanoids and isoflavanoids for the prevention and treatment of cardiovascular diseases |
| PT1807077T (pt) | 2004-10-22 | 2017-01-06 | Janssen Pharmaceutica Nv | Inibidores de quinase c-fms |
| ATE412636T1 (de) | 2004-12-16 | 2008-11-15 | Hoffmann La Roche | Piperazinylpyridinderivate als mittel gegen adipositas |
| TWI389897B (zh) | 2005-02-22 | 2013-03-21 | Chugai Pharmaceutical Co Ltd | 1- (2H) -isoquinolinone derivatives |
| RU2404973C2 (ru) | 2005-03-31 | 2010-11-27 | Астеллас Фарма Инк. | Производное соединение пропан-1,3-диона или его соль |
| NZ566180A (en) | 2005-07-29 | 2011-04-29 | Resverlogix Corp | Pharmaceutical compositions for the prevention and treatment of complex diseases and their delivery by insertable medical devices |
| JP2009506060A (ja) * | 2005-08-24 | 2009-02-12 | イノテック ファーマシューティカルズ コーポレイション | インデノイソキノリノン類縁体及びそれらの使用方法 |
| PT2090570E (pt) | 2006-09-05 | 2011-12-29 | Kyowa Hakko Kirin Co Ltd | Derivado de imidazole |
| US7772180B2 (en) | 2006-11-09 | 2010-08-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| ES2454966T3 (es) | 2007-02-01 | 2014-04-14 | Resverlogix Corp. | Compuestos para la prevención y el tratamiento de enfermedades cardiovasculares |
| FR2919286A1 (fr) * | 2007-07-27 | 2009-01-30 | Sanofi Aventis Sa | Derives de derives de 1-oxo-1,2-dihydroisoquinoleine-5- carboxamides et de 4-oxo-3,4-dihydroquinazoline-8- carboxamides,leur preparation et leur application en therapeutique. |
| US20090054392A1 (en) | 2007-08-20 | 2009-02-26 | Wyeth | Naphthylpyrimidine, naphthylpyrazine and naphthylpyridazine analogs and their use as agonists of the wnt-beta-catenin cellular messaging system |
| WO2009027650A1 (en) | 2007-08-24 | 2009-03-05 | The Institute Of Cancer: Royal Cancer Hospital | Materials and methods for exploiting synthetic lethality in brca-associated cancers |
| US20100267626A1 (en) | 2007-11-05 | 2010-10-21 | Novartis Ag | Methods and compositions for measuring wnt activation and for treating wnt-related cancers |
| DE102008019838A1 (de) | 2008-04-19 | 2009-12-10 | Boehringer Ingelheim International Gmbh | Neue Arylsulfonylglycin-Derivate, deren Herstellung und deren Verwendung als Arzneimittel |
| US8431704B2 (en) | 2008-04-22 | 2013-04-30 | Janssen Pharmaceutica Nv | Quinoline or isoquinoline substituted P2X7 antagonists |
| JP5743897B2 (ja) | 2008-11-20 | 2015-07-01 | グラクソスミスクライン・リミテッド・ライアビリティ・カンパニーＧｌａｘｏＳｍｉｔｈＫｌｉｎｅ ＬＬＣ | 化合物 |
| SG174252A1 (en) | 2009-03-06 | 2011-10-28 | Hoffmann La Roche | Heterocyclic antiviral compounds |
| CA2754509C (en) | 2009-03-18 | 2018-03-06 | Resverlogix Corp. | Novel anti-inflammatory agents |
| ES2706651T3 (es) | 2009-04-22 | 2019-03-29 | Resverlogix Corp | Nuevos agentes antiinflamatorios |
| TWI499418B (zh) | 2009-05-21 | 2015-09-11 | Nerviano Medical Sciences Srl | 異喹啉－１（２ｈ）－酮衍生物 |
| KR20120100913A (ko) | 2009-10-13 | 2012-09-12 | 엠에스데 오쓰 베.베. | 아세틸콜린 수용체에 관련된 질환의 치료를 위한 축합 아진 - 유도체 |
| CN103002738A (zh) | 2010-05-21 | 2013-03-27 | 英特利凯恩有限责任公司 | 用于激酶调节的化学化合物、组合物和方法 |
| JP2013528635A (ja) | 2010-06-17 | 2013-07-11 | ノバルティス アーゲー | ビフェニル置換１，３−ジヒドロ−ベンゾイミダゾール−２−イリデンアミン誘導体 |
| CN103781776A (zh) | 2011-07-13 | 2014-05-07 | 诺华股份有限公司 | 用作端锚聚合酶抑制剂的新的2-哌啶-1-基-乙酰胺化合物 |
| CN103814032A (zh) | 2011-07-13 | 2014-05-21 | 诺华股份有限公司 | 用作端锚聚合酶抑制剂的4-氧代-3,5,7,8-四氢-4H-吡喃并[4,3-d]嘧啶基化合物 |
| EP2731940B1 (en) | 2011-07-13 | 2015-08-19 | Novartis AG | 4 - piperidinyl compounds for use as tankyrase inhibitors |
| JP6106182B2 (ja) | 2011-11-25 | 2017-03-29 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | Ｐａｒｐ−１阻害剤としての３−フェニル−イソキノリン−１（２ｈ）−オン誘導体 |
| PT2797921T (pt) | 2011-12-31 | 2017-11-14 | Beigene Ltd | Dihidrodiazepinocarbazolonas tetra ou pentacíclicas fundidas como inibidoras de parp |
| KR101684039B1 (ko) | 2011-12-31 | 2016-12-07 | 베이진 엘티디 | Parp 저해제로서의 융합된 테트라 또는 펜타-사이클릭 피리도프탈라지논 |
| KR20140117641A (ko) | 2012-01-28 | 2014-10-07 | 메르크 파텐트 게엠베하 | 아자헤테로시클릭 화합물 |
| WO2013116182A1 (en) | 2012-01-31 | 2013-08-08 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds as inhibitors of leukotriene production |
| RS55377B1 (sr) | 2012-02-09 | 2017-03-31 | Merck Patent Gmbh | Derivati tetrahidro-hinazolinona kao inhibitori tank-a i parp-a |
| EP2822944A1 (en) | 2012-03-05 | 2015-01-14 | Amgen, Inc. | Oxazolidinone compounds and derivatives thereof |
| EP2822656B1 (en) | 2012-03-07 | 2016-10-19 | Institute of Cancer Research: Royal Cancer Hospital (The) | 3-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic use |
| CN104169284B (zh) | 2012-03-28 | 2017-03-29 | 默克专利股份公司 | 双环吡嗪酮衍生物 |
| US20130281397A1 (en) | 2012-04-19 | 2013-10-24 | Rvx Therapeutics Inc. | Treatment of diseases by epigenetic regulation |
| CN104271580B (zh) | 2012-05-04 | 2017-02-22 | 默克专利股份公司 | 吡咯并三嗪酮衍生物 |
| WO2013177349A2 (en) | 2012-05-25 | 2013-11-28 | Glaxosmithkline Llc | Quinazolinediones as tankyrase inhibitors |
| KR20150016406A (ko) | 2012-06-07 | 2015-02-11 | 에프. 호프만-라 로슈 아게 | 탄키라제의 피라졸로피리미돈 및 피라졸로피리돈 억제제 |
| CA2873723A1 (en) | 2012-06-07 | 2013-12-12 | F. Hoffmann-La Roche Ag | Pyrrolopyrimidone and pyrrolopyridone inhibitors of tankyrase |
| JP2015520205A (ja) | 2012-06-20 | 2015-07-16 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | タンキラーゼのピロロピラゾン阻害剤 |
| JP2015520204A (ja) | 2012-06-20 | 2015-07-16 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | タンキラーゼのピラノピリドン阻害剤 |
| SI2882714T1 (sl) | 2012-08-08 | 2020-03-31 | Merck Patent Gmbh | (aza-)izokinolinonski derivati |
| EP2890696A1 (en) | 2012-08-29 | 2015-07-08 | Amgen, Inc. | Quinazolinone compounds and derivatives thereof |
| WO2014045101A1 (en) | 2012-09-21 | 2014-03-27 | Cellzome Gmbh | Tetrazolo quinoxaline derivatives as tankyrase inhibitors |
| AR092211A1 (es) | 2012-09-24 | 2015-04-08 | Merck Patent Ges Mit Beschränkter Haftung | Derivados de hidropirrolopirrol |
| JP6276769B2 (ja) | 2012-09-26 | 2018-02-07 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | Ｐａｒｐインヒビターとしてのキナゾリノン誘導体 |
| WO2014087165A1 (en) | 2012-12-06 | 2014-06-12 | University Of Bath | Tankyrase inhibitors |
-
2013
- 2013-03-07 EP EP13709994.1A patent/EP2822656B1/en active Active
- 2013-03-07 CN CN201380023162.0A patent/CN104302358B/zh not_active Expired - Fee Related
- 2013-03-07 MX MX2014010509A patent/MX346147B/es active IP Right Grant
- 2013-03-07 IN IN1875MUN2014 patent/IN2014MN01875A/en unknown
- 2013-03-07 AU AU2013229229A patent/AU2013229229B2/en not_active Ceased
- 2013-03-07 ES ES13709994.1T patent/ES2611504T3/es active Active
- 2013-03-07 JP JP2014560442A patent/JP6082409B2/ja not_active Expired - Fee Related
- 2013-03-07 CA CA2865511A patent/CA2865511A1/en not_active Abandoned
- 2013-03-07 WO PCT/GB2013/050561 patent/WO2013132253A1/en active Application Filing
- 2013-03-07 KR KR1020147026143A patent/KR102104144B1/ko not_active Expired - Fee Related
- 2013-03-07 US US14/381,712 patent/US9193689B2/en not_active Expired - Fee Related
- 2013-03-07 DK DK13709994.1T patent/DK2822656T3/en active
- 2013-03-07 RU RU2014138194A patent/RU2696572C2/ru not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| US20150099732A1 (en) | 2015-04-09 |
| ES2611504T3 (es) | 2017-05-09 |
| WO2013132253A1 (en) | 2013-09-12 |
| CN104302358A (zh) | 2015-01-21 |
| RU2014138194A (ru) | 2016-04-27 |
| EP2822656A1 (en) | 2015-01-14 |
| KR102104144B1 (ko) | 2020-04-23 |
| JP2015512885A (ja) | 2015-04-30 |
| CA2865511A1 (en) | 2013-09-12 |
| DK2822656T3 (en) | 2017-01-30 |
| AU2013229229B2 (en) | 2017-10-19 |
| RU2696572C2 (ru) | 2019-08-05 |
| US9193689B2 (en) | 2015-11-24 |
| MX2014010509A (es) | 2014-10-14 |
| KR20150001734A (ko) | 2015-01-06 |
| IN2014MN01875A (OSRAM) | 2015-07-03 |
| EP2822656B1 (en) | 2016-10-19 |
| AU2013229229A1 (en) | 2014-09-25 |
| JP6082409B2 (ja) | 2017-02-15 |
| CN104302358B (zh) | 2017-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX346147B (es) | Compuestos de 3-aril-5-substituido-isoquinolin-1-ona y su uso terapeutico. | |
| MX2014004861A (es) | Benzopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr). | |
| PH12014500867A1 (en) | Anticancer pyridopyrazines via the inhibition of fgfr kinases | |
| MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
| PH12014502772A1 (en) | Substituted tricyclic compounds as fgfr inhibitors | |
| NZ708382A (en) | Cycloalkyl bis-thiadiazole inhibitors of glutaminase and their use as therapeutic agents | |
| IN2014KN02601A (OSRAM) | ||
| IN2012MN02591A (OSRAM) | ||
| IN2015DN01156A (OSRAM) | ||
| MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
| NZ707778A (en) | Therapeutic compounds and compositions and their use as pkm2 modulators | |
| IN2014MN02069A (OSRAM) | ||
| MX2013004307A (es) | Derivados de arilamida como bloqueadores de ttx-s. | |
| PH12014502032A1 (en) | Treatment of brain cancer | |
| PH12014501581A1 (en) | Tetrahydro-quinazolinone derivatives as tank and parp inhibitors | |
| MX360323B (es) | Derivados de pirrolopiridinona como bloqueadores de ttx-s. | |
| MX2016004094A (es) | Composicion farmaceutica que comprende capecitabina y ciclofosfamida. | |
| GB2519004A (en) | Quinone compounds and their uses for the treatment of cancer | |
| PH12016502133A1 (en) | Substituted tricycle compounds as fgfr inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |